MedImmune touts FluMist results

In a test of 8,492 children in 16 countries, FluMist maker MedImmune found that a new version of its nasal spray flu vaccine was more effective than the standard flu shot for children. The result of this study is a major victory for MedImmune given FluMist's poor sales even during flu shot shortages. As The Washington Post reports, "[t]he $90 million study was MedImmune's last-ditch effort to revive FluMist by proving the product was better at preventing the flu in children under five--a crucial age group for whom regulators did not originally recommend the vaccine when they approved it in 2003."

- read this article from The Washington Post